-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

Benzinga·08/04/2026 14:07:48
Listen to the news
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.